Major Growth Driver Identified in 2025 Pulmonary Arterial Hypertension Market: Elevated Prevalence Of Pulmonary Arterial Hypertension (PAH) Driving Market Growth

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

Pulmonary Arterial Hypertension Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for pulmonary arterial hypertension has seen robust expansion in recent years. It is forecasted to increase from $8.47 billion in 2024 to $9.24 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.1%. Factors such as heightened awareness and detection of pulmonary arterial hypertension (PAH), growth in healthcare spending, an aging population, expansion of treatment options for pulmonary arterial hypertension, and increased research and development activities in the field of pulmonary hypertension have contributed to the growth experienced during the historical period.

Pulmonary Arterial Hypertension Market Size Forecast: What's the Projected Valuation by 2029?
Expectations are high for the pulmonary arterial hypertension market to experience robust growth in the upcoming years. The market size is projected to expand to $12.97 billion in 2029, with a compound annual growth rate (CAGR) of 8.8%. This growth within the projected timeframe can be credited to several factors including the rise in adoption of innovative therapies for pulmonary arterial hypertension, a heightened emphasis on early identification and diagnosis, a burgeoning pipeline of PAH drugs and healing procedures, precision medicine's role in PAH treatment, and the development of healthcare infrastructure in rising markets. Prominent trends predicted for this period comprise advancements in medical imaging and diagnostic technologies, alliances and partnerships for drug development, patient-focused methodologies in managing pulmonary arterial hypertension, and an amplified utilization of combination therapy.

View the full report here:
https://www.thebusinessresearchcompany.com/report/pulmonary-arterial-hypertension-global-market-report

What Are the Drivers Transforming the Pulmonary Arterial Hypertension Market?
The rise in instances of pulmonary arterial hypertension (PAH) disease is fuelling the expansion of the PAH market. The surging rate of PAH diseases and the associated hospital admissions for treatment are anticipated to stimulate demand for corresponding medicines throughout the projected timeline. As per research conducted by the National Organization for Rare Disorders, Inc., fresh incidents of PAH are calculated to emerge in one to two persons per million every year in the USA, translating to 500-1000 new cases annually, and Europe is anticipated to reveal comparable rates of occurrence.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=5954&type=smp

What Long-Term Trends Will Define the Future of the Pulmonary Arterial Hypertension Market?
Leading businesses in the pulmonary arterial hypertension market are pioneering new products like Winrevair to bolster the treatment alternatives and outcome for patients afflicted with this critical condition. For instance, Merck & Co. Inc, an American multinational pharmaceutical firm, unveiled Winrevair in March 2024 for treating adults suffering from pulmonary arterial hypertension. The therapy, the first to be approved by the US-based Food and Drug Administration (FDA) targets activin signaling for treating PAH. This groundbreaking treatment achieves its results by reinstating the equilibrium between pro- and anti-proliferative cues, ultimately regulating the vascular cell proliferation pertinent to PAH. Consequently, it paves the way for a novel treatment category for this ailment.

Which Segments in the Pulmonary Arterial Hypertension Market Offer the Most Profit Potential?
The pulmonary arterial hypertension market covered in this report is segmented -

1) By Drug Class: Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators
2) By Route Of Administration: Oral, Intravenous Or subcutaneous, Inhalational
3) By Distribution channel: Retail, Online

Subsegments:
1) By Endothelin Receptor Antagonists (ERAs): Bosentan, Ambrisentan, Macitentan
2) By PDE-5 Inhibitors: Sildenafil, Tadalafil
3) By Prostacyclin And Prostacyclin Analogs: Epoprostenol, Treprostinil, Iloprost
4) By SGC Stimulators: Riociguat

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=5954&type=smp

Which Firms Dominate the Pulmonary Arterial Hypertension Market by Market Share and Revenue in 2025?
Major companies operating in the pulmonary arterial hypertension market include United Therapeutics Corporation, Acceleron Pharma Inc., Actelion Pharmaceuticals US Inc., Bayer AG, Eli Lilly and Company, Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Liquidia Technologies Inc., Lupin Pharmaceuticals Inc., Natco Pharma Ltd., Pfizer Inc., Sandoz AG, Teva Pharmaceutical Industries Ltd., Zydus Pharmaceutical USA Inc., Allegheny Health Network, Cedars-Sinai Medical Center, Cleveland Clinic, Houston Methodist Hospital, Johns Hopkins Medicine, Massachusetts General Hospital, Mayo Clinic, MedStar Heart & Vascular Institute, National Jewish Health, NewYork-Presbyterian Hospital, Ochsner Medical Center, Royal Brompton & Harefield NHS Foundation Trust, Rush University Medical Center, Stanford Health Care, Swedish Medical Center, Temple University Hospital, University of California Health.

Which Regions Offer the Highest Growth Potential in the Pulmonary Arterial Hypertension Market?
North America was the largest region in the pulmonary arterial hypertension market in 2024. The regions covered in the pulmonary arterial hypertension market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=5954

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.